 | This article contains content that is written like an advertisement. (February 2021) |
Rudi Pauwels | |
|---|---|
 Dr. Rudi Pauwels | |
| Born | 1960 |
| Nationality | Belgian |
| Education | Ph.D. in pharmaceutical sciences |
| Alma mater | KU Leuven |
| Occupation(s) | Pharmaceutical scientist and biotech entrepreneur |
| Organization(s) | Praesens Foundation, Praesens Care, miDiagnostics |
| Awards | Prix Galien MedStartUpAward (2019), Global Technology Pioneer Award (2012), INSEAD Innovator Prize (2002) |
Rudi Pauwels (born 1960) is a Belgian pharmacologist and biotech entrepreneur.[1]
He was one of the first researchers in the field of HIV, and he played a key role in the fight against the AIDS pandemic by discovering several widely used anti-HIV drugs during his doctorate studies at the Rega Institute (Leuven, Belgium) and while leading biotech companies Tibotec and Virco.[2]
Since 1994 he has either founded or co-founded several biotech companies, specialising in personalized and high precision medicine. His current roles include founder and president of the Praesens Foundation, chairman of Praesens Care, executive chairman of IMEC/Johns Hopkins spin-off company miDiagnostics and board positions in various companies and research institutes. He is an author of more than 150 peer-reviewed papers and recipient of numerous awards and distinctions.[3][4]
In 2020 he was appointed as co-chair of the Diagnostics R&D Working Group of the Access to COVID-19 Tools Accelerator.[5][failed verification][6]
- ^ "Coronavirus Global Response International Pledging Conference Countdown - Rudi Pauwels". global-response.europa.eu. Retrieved 4 February 2021.
- ^ "Rudi Pauwels: Pionier in AIDS preventie en ziektedetectie" (PDF). Trends (in Dutch): 78–79. 2014 – via Knack.
- ^ "Interview: "Het gebrek aan langetermijnvisie is de ziekte van deze tijd"". Trends. 1167021. 2018.
- ^ "Rudi Pauwels' research". ResearchGate. 2021. Retrieved 4 February 2021.
- ^ "About the ACT-Accelerator". FIND. Retrieved 4 February 2021.
- ^ "ACT Accelerator: global response to COVID-19. ACT-A Dx structure" (PDF). Global Health Hub. Retrieved 4 February 2021.